Search
Multiple Sclerosis Paid Clinical Trials in Colorado
A listing of 19 Multiple Sclerosis clinical trials in Colorado actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 19 of 19
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Multiple Sclerosis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Colorado currently has 19 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2025
Locations: Mountain Neuro Research Center PC, Basalt, Colorado +1 locations
Conditions: Relapsing Multiple Sclerosis
Study to Evaluate Efficacy of a Modified Regimen of Ublituximab
Recruiting
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab as measured by T1 Gadolinium (Gd)-enhancing lesions.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/27/2025
Locations: TG Investigational Site, Fort Collins, Colorado
Conditions: Relapsing Multiple Sclerosis
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.
All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: Rocky Mountain Multiple Sclerosis Center, University of Colorado School of Medicine, Aurora, Colorado
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS
Recruiting
The objective of the randomized, sham-controlled trial will be to evaluate the effectiveness of treatment with transcutaneous electrical nerve stimulation (TENS) at reducing the level of fatigue experienced by people with MS.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/05/2024
Locations: University of Colorado, Boulder, Colorado
Conditions: Multiple Sclerosis
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Recruiting
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Relapsing Multiple Sclerosis
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
Recruiting
The goal of this observational study is to longitudinally investigating subjects with inaugural acute optic neuritis (ON).
The main questions it aims to answer are:
* Does the time to corticosteroid treatment affect the visual outcome at 6 months in subjects with acute multiple sclerosis (MS)-, aquaporin 4-IgG positive (AQP4-IgG+) and myelin-oligodendrocyte-glycoprotein-IgG positive (MOG-IgG+) ON?
* How differ clinical, structural, and laboratory biomarkers in subjects with acute ON, including... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2022
Locations: University of Colorado School of Medicine, Aurora, Colorado
Conditions: Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Optic Neuritis
Home Based Infusions for Ocrelizumab
Recruiting
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/08/2021
Locations: Amerita, Centennial, Colorado
Conditions: Multiple Sclerosis
13 - 19 of 19